Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.63USD
21 Jul 2017
Change (% chg)

$-0.31 (-0.49%)
Prev Close
$62.94
Open
$62.80
Day's High
$62.99
Day's Low
$62.58
Volume
2,772,353
Avg. Vol
2,925,936
52-wk High
$66.80
52-wk Low
$57.18

Latest Key Developments (Source: Significant Developments)

European Medicines Agency's CHMP recommends approval for Merck's Keytruda
Friday, 21 Jul 2017 07:31am EDT 

July 21 (Reuters) - Merck & Co Inc :European Medicines Agency's CHMP recommends approval for Merck's Keytruda® (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.Says ‍final decision is expected in Q3 of 2017​.Merck-‍ Positive opinion based on overall survival benefit demonstrated in phase 3 keynote-045 trial, durable responses observed in phase 2 keynote-052 trial​.  Full Article

Merck announces U.S. FDA grants tentative approval for Lusduna™ Nexvue™
Thursday, 20 Jul 2017 07:30am EDT 

July 20 (Reuters) - Merck & Co Inc :Merck announces U.S. FDA grants tentative approval for Lusduna™ Nexvue™ (insulin glargine injection), a follow-on biologic basal insulin.Says trade name "lusduna nexvue" was granted provisional approval by FDA.  Full Article

Lannett receives approval for Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
Friday, 14 Jul 2017 06:53am EDT 

July 14 (Reuters) - Lannett Company Inc :Lannett receives approval for cyproheptadine hydrochloride syrup, 2 mg/5 ml.Lannett company inc - ‍product was previously marketed under brand name periactin syrup, 2 mg/5 ml of merck and co., inc.​.  Full Article

Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck
Thursday, 13 Jul 2017 08:00am EDT 

July 13 (Reuters) - Aduro Biotech Inc :‍​:Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody​.‍Aduro announces milestone achieved relating to collaboration with merck for development of anti-cd27 antibody for treatment of cancer​.  Full Article

PDS Biotechnology enters a clinical trial collaboration agreement with a subsidiary of Merck
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Merck & Co Inc :PDS Biotechnology says has entered a clinical trial collaboration agreement with a subsidiary of Merck.Agreement to evaluate combination of PDS's lead PDS0101, with Merck's anti-PD-1 therapy, Keytruda in a phase II clinical trial.Says details of collaboration were not disclosed.  Full Article

Merck to present new data from clinical trials at IAS 2017
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Merck & Co Inc :Merck to present new data from clinical trials evaluating Isentress HD (raltegravir) and investigational HIV therapies Doravirine and MK-8591 at IAS 2017.Merck says late-breaker abstract will be presented of a phase 1 study of MK-8591, Merck's investigational NRTTI in adult patients with HIV-1 infection​.Merck - ‍recommendation is under review by European commission for marketing authorization in EU with decision on approval expected in H2 of 2017​.  Full Article

Merck provides further update on 3 multiple myeloma studies evaluating Keytruda in combination with Pomalidomide, Lenalidomide
Wednesday, 5 Jul 2017 04:30pm EDT 

July 5 (Reuters) - Merck & Co Inc ::Merck provides further update on three multiple myeloma studies evaluating Keytruda® (pembrolizumab) in combination with pomalidomide or lenalidomide.Merck provides further update on three multiple myeloma studies evaluating Keytruda® (pembrolizumab) in combination with pomalidomide or lenalidomide.Merck & Co Inc - U.S. Food and drug administration (FDA) has placed a clinical hold on keynote-183, keynote-185 and keynote-023.Merck & co inc - ‍decision follows a review of data by dmc in which more deaths were observed in Keytruda arms of keynote-183 and keynote-185​.Merck - FDA determined data available indicates risks of Keytruda + pomalidomide or lenalidomide outweigh potential benefit for patients with multiple myeloma.Merck & co inc - clinical hold does not apply to other studies with Keytruda.Merck & co - ‍all patients enrolled in keynote-183,keynote-185 will discontinue investigational treatment with Keytruda​.Merck & co - patients enrolled in Keytruda/lenalidomide/dexamethasone cohort in keynote-023 will also discontinue investigational treatment with Keytruda​.  Full Article

Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study
Wednesday, 21 Jun 2017 05:41pm EDT 

June 21 (Reuters) - Leap Therapeutics Inc -:Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg).Leap Therapeutics Inc says under agreement, merck will be responsible for manufacturing and supplying Keytruda(reg) for clinical trials - sec filing.Leap Therapeutics Inc - agreement provides that both Leap and Merck will jointly own clinical data generated from this clinical trial.  Full Article

Leap Therapeutics announces collaboration with Merck
Wednesday, 21 Jun 2017 09:07am EDT 

June 21 (Reuters) - Leap Therapeutics Inc :Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer.Leap therapeutics inc - additional details of collaboration were not disclosed..Leap therapeutics inc - collaboration agreement is between leap and merck, through a subsidiary.Leap therapeutics inc - study is expected to begin enrolling patients in second-half of 2017.  Full Article

PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications
Tuesday, 20 Jun 2017 03:37pm EDT 

June 20 (Reuters) - PV Nano Cell Ltd::Is entering a cooperation with Merck to develop technology applications for single-crystalline metal particles.  Full Article

Photo

Trump unveils companies' $500 million U.S. drug packaging project

WASHINGTON President Donald Trump on Thursday announced a $500 million investment that Corning Inc is making with pharmaceutical giants Merck and Pfizer to manufacture a new kind of glass for injectable drug vials.